KeyBanc downgraded Ardent Health (ARDT) to Sector Weight from Overweight without a price target following the Q3 report. The company’s EBITDA baseline exiting 2025 “seems less certain” and KeyBanc’s 2026 estimates are moving materially lower, the analyst tells investors in a research note. The firm cites Ardent’s emerging pressures from payor denials and professional fees in radiology for the downgrade. It would like to gain confidence that these issues aren’t getting worse before again recommending the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Cautious Outlook on Ardent Health Partners, Inc. Amidst Uncertainty in Financial Projections and Rising Costs
- Ardent Health Partners, Inc.: Buy Rating Affirmed Amid Low Valuation and Cost-Saving Potential
- Ardent Health price target lowered to $16 from $23 at Leerink
- Ardent Health price target lowered to $16 from $21 at RBC Capital
- Ardent Health price target lowered to $17 from $19 at Loop Capital